- Case Report
- Open Access
Successful thoracic duct identification with patent blue V during thoracic duct ligation for chylothorax: a case report
General Thoracic and Cardiovascular Surgery Cases volume 1, Article number: 7 (2022)
Chylothorax after thoracic surgery is a rare but severe complication. When thoracic duct ligation is performed for chylothorax, identification of the leakage site and the thoracic duct course is necessary. Administering milk orally or through a nasogastric tube and injecting indocyanine green into lymph nodes and lymphatic vessels can be performed to identify the leakage site and the thoracic duct course. However, the injection of patent blue V into the inguinal lymph nodes has not been reported.
A 69-year-old man underwent aortic replacement surgery for an aortic aneurysm of the distal arch. On postoperative day 3, after resuming oral intake, the patient was diagnosed with chylothorax. The patient was treated with fasting and total parenteral nutrition, but the chylous pleural effusion continued at 500–1000 ml daily. A plan for thoracic duct ligation was made. We injected patent blue V into the inguinal lymph node to identify the leakage site and the thoracic duct course. The blue-stained thoracic duct was identified and ligated, but the leakage site could not be identified because of the surrounding lung adhesions. The thoracic drain was removed on day 6 post-second operation, and the chylothorax did not recur.
Identifying the thoracic duct course using patent blue V is useful during thoracic duct ligation for chylothorax.
Chylothorax is a rare but severe complication of thoracic surgery. Treatments for chylothorax includes a low-fat medium-chain triglyceride diet, fasting, total parenteral nutrition (TPN), octreotide acetate, pleurodesis, thoracic duct embolization, and thoracic duct ligation (TDL) [1,2,3,4,5]. The treatment method is selected according to the drainage volume of the chylous pleural effusion and the patient's condition. When performing TDL, it is necessary to identify the leakage site of the chylous pleural effusion and thoracic duct (TD) course intraoperatively. Administering a high-fat diet, such as milk or olives orally or through a nasogastric tube during TDL, has been reported [3, 4]. Indocyanine green (ICG) injection into lymph nodes and vessels has also been performed [5, 6].
Patent blue V is used during lymphangiography to stain lymph nodes and vessels blue. It can also identify sentinel lymph nodes in breast cancer . However, its use for identifying the leakage site and the TD course during TDL has not been reported. We report a case in which the TD course was identified using patent blue V during TDL for chylothorax after surgery for a thoracic aortic aneurysm.
A 69-year-old man underwent aortic replacement surgery using a prosthetic graft for an aortic aneurysm of the distal arch. On postoperative day 3, after he started oral intake, the pleural effusion from the thoracic drain became chylous, and he was diagnosed with chylothorax. The patient was treated with fasting and TPN, but the chylous pleural effusion continued at 500–1000 ml daily. Lymphangiography was performed on postoperative day 7 to identify the leakage site and TD course. The right inguinal lymph node was confirmed using ultrasound, punctured with a 23-G catheter needle (Terumo, Tokyo, Japan), and injected with iomeprol (Iomeron, Eisai, Tokyo, Japan). After confirming fluoroscopic contrast of the intra-abdominal chyle vessels, Lipiodol (Guerbet Japan, Tokyo, Japan) was injected into the lymph nodes. The fluoroscopic X-ray image showed two thoracic ducts without any connections (Fig. 1a). No cisterna chyli was observed in the abdominal cavity (Fig. 1b). The leakage site was observed in the thoracic duct running through the left thoracic cavity (Fig. 1c, d). A subsequent chest computed tomography scan showed similar findings (Fig. 2a–c). On postoperative day 8, octreotide acetate (Sun Pharma Japan Ltd., Tokyo, Japan) was administered. However, the chylous pleural effusion did not decrease. On postoperative day 21, we scheduled the patient for TDL. We used patent blue V (Sigma-Aldrich Japan GK, Tokyo, Japan) to identify the leakage site and TD course. In Japan, this is an off-label use; therefore, we received approval from the Ethics Committee of Fujita Health University Hospital (approval number: 09–8). After the induction of general anesthesia, 2 ml of 10% patent blue V mixed with 2 ml of iohexol (Omnipaque; GE Healthcare Japan, Tokyo, Japan) were injected into the inguinal lymph node at less than 0.8 ml/min under ultrasound guidance. Video-assisted thoracoscopic surgery was performed after confirming that the intra-abdominal chyle vessels were contrasted using fluoroscopic X-ray imaging. Thoracoscopy revealed patent blue V leakage in the left thoracic cavity; however, lung adhesions were observed in the surrounding area (Fig. 3a, b). While it was necessary to separate the adhesions to identify the leakage site, we decided against it to avoid lung injury. We identified a blue-colored TD in the dorsal aortic connective tissue (Fig. 3c, d), which were clipped using a DS clip (B. Braun Aesculap Japan Co., Ltd., Tokyo, Japan) (Fig. 3e). The operation time was approximately 120 min, and we could visualize the TD until the end of the operation. After the operation, blue pigmentation was observed on the patient's entire body and persisted until day 2. Oral intake was started on day 4, and the chylous pleural effusion did not increase. The thoracic drain was removed on day 6. Chylothorax did not recur and the patient was discharged from the hospital 14 days after the second surgery.
Discussion and conclusions
Conservative treatment, such as a low-fat medium-chain triglyceride diet, fasting, and TPN, are treatment options for chylothorax [1,2,3]. Takuwa et al. reported that 23 out of 37 patients with chylothorax after lung cancer surgery were successfully treated with a low-fat diet . However, the remaining 14 patients required pleurodesis or surgical intervention. In the present case, the patient was not successfully treated with fasting and TPN and ultimately underwent surgery.
Pleurodesis using multiple chemicals or autologous blood is one of the treatments for chylothorax [1,2,3]. Pleurodesis can control especially low levels of pleural effusion and was considered in our hospital because the pleural effusion was 500–1000 ml daily after fasting and TPN. However, pyothorax is a potential complication of pleurodesis, and since the patient had undergone aortic replacement with a prosthetic graft, pyothorax may have resulted in potentially fatal graft infection. In addition, adhesions in the thoracic cavity would have made subsequent TDL challenging. Therefore, pleurodesis was not performed.
Lymphatic embolization is another treatment option . It requires cannulation of the catheter from the cisterna chyli, and advancing it to reach the leakage site. The patient had no cisterna chyli, precluding catheter insertion, and ruling out lymphatic embolization.
For the reasons above, we performed TDL. Administering milk or olives stains the TD white and allows for identification of its course and the leakage site [3, 4]. We chose patent blue V, because we believed that a blue stain would be more visible. As a result, a blue-stained TD on the dorsal side of the aorta appeared although we could not identify the leakage site because of lung adhesions. If milk or olives cannot be used due to allergies, this method might be a viable alternative.
Barthelmes et al. reported that the side effects of patent blue V when identifying sentinel lymph nodes in breast cancer were allergic reactions (0.85%), skin tattooing (0.012%), and a bluish hue persisting for a few hours (0.037%) . In our case, blue pigmentation of the entire body persisted for 2 days after the second operation. However, we used 10% patent blue V compared to only 2.5% in Barthelmes et al.’s report. This significantly higher concentration may have caused the prolonged pigmentation.
Recently, ICG injection into lymph nodes or lymphatic vessels to identify the leakage site of chylous pleural effusion and the TD course has been reported [5, 6]. However, this method requires dedicated fluorescence imaging equipment, while one advantage of patent blue V is not requiring specific equipment.
We report a case of successful identification of the TD course using patent blue V. Our approach may be useful during TDL for chylothorax after thoracic surgery.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Total parenteral nutrition
Thoracic duct ligation
Takuwa T, Yoshida J, Ono S, Hishida T, Nishimura M, Aokage K, et al. Low-fat diet management strategy for chylothorax after pulmonary resection and lymph node dissection for primary lung cancer. J Thorac Cardiovasc Surg. 2013;146:571–4.
Bryant AS, Minnich DJ, Wei B, Cerfolio RJ. The incidence and management of postoperative chylothorax after pulmonary resection and thoracic mediastinal lymph node dissection. Ann Thorac Surg. 2014;98:232–7.
Reisenauer JS, Puig CA, Reisenauer CJ, Allen MS, Bendel E, Cassivi SD, et al. Treatment of postsurgical chylothorax. Ann Thorac Surg. 2018;105:254–62.
Shen Y, Feng M, Khan MA, Wang H, Tan L, Wang Q. A simple method minimizes chylothorax after minimally invasive esophagectomy. J Am Coll Surg. 2014;218:108–12.
Vecchiato M, Martino A, Sponza M, Uzzau A, Ziccarelli A, Marchesi F, et al. Thoracic duct identification with indocyanine green fluorescence during minimally invasive esophagectomy with patient in prone position. Dis Esophagus. 2020;33:1–6.
Yang F, Zhou J, Li H, Yang F, Xiao R, Chi C, et al. Near-infrared fluorescence-guided thoracoscopic surgical intervention for postoperative chylothorax. Interact Cardiovasc Thorac Surg. 2018;26:171–5.
Barthelmes L, Goyal A, Newcombe RG, McNeill F, Mansel RE. Adverse reactions to patent blue V dye - The NEW START and ALMANAC experience. Eur J Surg Oncol. 2010;36:399–403.
We want to thank Editage (www.editage.com) for English language editing.
Medical expenses for patent blue V were paid by the research fund of the Department of Radiology, Fujita Health University School of Medicine.
Ethics approval and consent to participate
The Ethics Committee of Fujita Health University Hospital approved the use of patent Blue V (approval number: 09–8). Informed consent for the use of patent blue V was obtained from the patient.
Consent for publication
Written informed consent was obtained from the patient to publish this case report and associated images.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Suzuki, Y., Yamana, K., Ishizawa, H. et al. Successful thoracic duct identification with patent blue V during thoracic duct ligation for chylothorax: a case report. Gen Thorac Cardiovasc Surg Cases 1, 7 (2022). https://doi.org/10.1186/s44215-022-00010-5
- Thoracic duct ligation
- Patent blue
- Video-assisted thoracic surgery